Misfolded proteins and neurodegeneration: Role of non-native cytochrome c in cell death

Expert Review of Proteomics

Volumn 7, Issue 4, 2010, Pages 507-517

  Santucci, Roberto ^a   Sinibaldi, Federica ^a   Patriarca, Antonella ^a   Santucci, Daniele ^a   Fiorucci, Laura ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

apoptosis; cardiolipin; cytochrome c; minocycline; misfolding; neurodegenerative disease; protein folding

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; ASCORBIC ACID; CARDIOLIPIN; CYTOCHROME C; DOPA; HEME; MINOCYCLINE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UBIDECARENONE;

ALZHEIMER DISEASE; APOPTOSIS; CANCER CELL; CELL SURVIVAL; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG TARGETING; ENZYME STRUCTURE; HUMAN; MITOCHONDRIAL MEMBRANE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN PROCESSING; REVIEW;

APOPTOSIS; CARDIOLIPINS; CYTOCHROMES C; HUMANS; NERVE DEGENERATION; PEROXIDASE; PROTEOSTASIS DEFICIENCIES;

EID: 77955010738     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.50     Document Type: Review

References (102)

1. Gregersen N, Bross P, Vang S, Christensen JH. Protein misfolding and human disease. Annu. Rev. Genomics Hum. Genet. 7, 103-124 (2006).
2. Santucci R, Sinibaldi F, Fiorucci L. Protein folding, unfolding and misfolding. Role played by intermediate states. Mini Rev. Med. Chem. 8(1), 57-62 (2008).
3. Gooptu B, Lomas DA. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu. Rev. Biochem. 78, 147-176 (2009).
4. Kupfer L, Hinrichs W, Groschup MH. Prion protein misfolding. Curr. Mol. Med. 9, 826-835 (2009).
5. Querfurth HW, LaFerla FM. Alzheimer's disease. N. Engl. J. Med. 362, 329-344 (2010).
6. Roder H, Maki K, Cheng H, Shastry MC. Rapid mixing methods for exploring the kinetics of protein folding. Methods 34(1), 15-27 (2004).
7. Wolynes PG. Recent successes of the energy landscape theory of protein folding and function. Q. Rev. Biophys. 38(4), 405-410 (2005).
8. Lindorff-Larsen K, Røgen P, Paci E, Vendruscolo M, Dobson CM. Protein folding and the organization of the protein topology universe. Trends Biochem. Sci. 30(1), 13-19 (2005). (Pubitemid 40093736)
9. Laskowska E, Matuszewska E, Kuczynska-Wisnik D. Small heat shock proteins and protein-misfolding diseases. Curr. Pharm. Biotechnol. 11(2), 146-157 (2010).
10. Cutting GR. Modifier genetics: cystic fibrosis. Rev. Genomics Hum. Genet. 6, 237-260 (2005).
11. MacDonald KD, McKenzie KR, Zeitlin PL. Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. Pediatr. Drugs 9(1), 1-10 (2007).
12. Shirley ED, Sponseller PD. Marfan syndrome. J. Am. Acad. Orthop. Surg. 17(9), 572-581 (2009).
13. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 372 (9647), 1427-1435 (2008).
14. Boot RG, van Breemen MJ, Wegdam W et al. Gaucher disease: a model disorder for biomarker discovery. Expert Rev. Proteomics 6(4), 411-419 (2009).
15. Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr. Opin. Oncol. 22(1), 64-69 (2010).
16. Wetzel R, Shivaprasad S, Williams AD. Plasticity of amyloid fibrils. Biochemistry 46(1), 1-10 (2007).
17. Douglas MR, Lewthwaite AJ, Nicholl DJ. Genetics of Parkinson's disease and parkinsonism. Expert Rev. Neurother. 7(6), 657-666 (2007).
18. Uversky VN, Eliezer D. Biophysics of Parkinson's disease: structure and aggregation of a-synuclein. Curr. Protein Pept. Sci. 10(5), 483-499 (2009).
19. Fändrich M, Meinhardt J, Grigorieff N. Structural polymorphism of Alzheimer Ab and other amyloid fibrils. Prion 3(2), 89-93 (2009).
20. Baldwin RL. The search for folding intermediates and the mechanism of protein folding. Annu. Rev. Biophys. 37, 1-21 (2008).
21. Murphy RM. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. Biochim. Biophys. Acta 1768(8), 1923-1934 (2007).
22. Ptitsyn OB. The molten globule state. In: Protein Folding. Creighton TE (Ed.). Freeman and Company, NY, USA 243-300 (1992).
23. Englander SW, Mayne L, Krishna MM. Protein folding and misfolding: mechanism and principles. Q. Rev. Biophys. 40(4), 287-326 (2007).
24. Seshadri S, Oberg KA, Uversky VN. Mechanisms and consequences of protein aggregation: the role of folding intermediates. Curr. Protein Pept. Sci. 10(5), 456-463 (2009).
25. Onuchic JN, Wolynes PG. Theory of protein folding. Curr. Opin. Struct. Biol. 14(1), 70-75 (2004).
26. Oliveberg M, Wolynes PG. The experimental survey of protein-folding energy landscapes. Q. Rev. Biophys. 38(3), 245-288 (2005).
27. Wales DJ. Energy landscapes: some new horizons. Curr. Opin. Struct. Biol. 20, 3-10 (2010).
28. Weinkam P, Romesberg FE, Wolynes PG. Chemical frustration in the protein folding landscape: grand canonical ensemble simulations of cytochrome c. Biochemistry 48(11), 2394-2402 (2009).
29. Borgia A, Williams PM, Clarke J. Single-molecule studies of protein folding. Annu. Rev. Biochem. 77, 101-125 (2008).
30. Schuler B, Eaton WA. Protein folding studied by single-molecule FRET. Curr. Opin. Struct. Biol. 18(1), 16-26 (2008).
31. Dobson CM. Principles of protein folding, misfolding and aggregation. Semin. Cell Dev. Biol. 15(1), 3-16 (2004).
32. Lee TW, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem. J. 387, 1-15 (2005).
33. Amaral MD. Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease. J. Inherit. Metab. Dis. 29(2-3), 477-487 (2006).
34. Mendes F, Farinha CM, Roxo-Rosa M et al. Antibodies for CFTR studies. J. Cyst. Fibros. 3, 69-72 (2004).
35. Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol. Sci. 28(7), 334-341 (2007).
36. Yancey PH. Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses. J. Exp. Biol. 208(Pt 15), 2819-2830 (2005).
37. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959-991 (2009).
38. Roxo-Rosa M, Davezac N, Bensalem N et al. Proteomics techniques for cystic fibrosis research. J. Cyst. Fibros. 3(2), 85-89 (2004).
39. Davezac N, Tondelier D, Lipecka J et al. Global proteomic approach unmasks involvement of keratins 8 and 18 in the delivery of cystic fibrosis transmembrane conductance regulator (CFTR)/DF508-CFTR to the plasma membrane. Proteomics 4(12), 3833-3844 (2004).
40. Ollero M, Brouillard F, Edelman A. Cystic fibrosis enters the proteomics scene: new answers to old questions. Proteomics 6(14), 4084-4099 (2006).
41. Gharib SA, Vaisar T, Aitken ML, Park DR, Heinecke JW, Fu X. Mapping the lung proteome in cystic fibrosis. J. Proteome Res. 8(6), 3020-3028 (2009).
42. Gomes-Alves P, Couto F, Pesquita C, Coelho AV, Penque D. Rescue of F508del-CFTR by RXR motif inactivation triggers proteome modulation associated with the unfolded protein response. Biochim. Biophys. Acta 1804(4), 856-865 (2010).
43. Chiti F, Dobson CM. Amyloid formation by globular proteins under native conditions. Nat. Chem. Biol. 5(1), 15-22 (2009).
44. Luheshi LM, Dobson CM. Bridging the gap: from protein misfolding to protein misfolding diseases. FEBS Lett. 583, 2581-2586 (2009).
45. Kodali R, Wetzel R. Polymorphism in the intermediates and products of amyloid assembly. Curr. Opin. Struct. Biol. 17, 48-57 (2007).
46. Van Broeck B, Van Broeckhoven C, Kumar-Singh S. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Neurodegener. Dis. 4, 349-365 (2007).
47. Moloney A, Sattelle DB, Lomas DA, Crowther DC. Alzheimer's disease: insights from Drosophila melanogaster models. Trends Biochem. Sci. 35(4), 228-235 (2010).
48. Hsu M-J, Sheu J-R, Lin C-H, Shen M-Y, Hsu Cy. Mitochondrial mechanisms in amyloid b peptide-induced cerebrovascular degeneration. Biochim. Biophys. Acta 1800, 290-296 (2010).
49. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366 (2006).
50. Jager M, Deechongkit S, Koepf EK et al. Understanding the mechanism of b-sheet folding from a chemical and biological perspective. Biopolymers 90(6), 751-758 (2008).
51. Pedersen JS, Christensen G, Otzen DE. Modulation of S6 fibrillation by unfolding rates and gatekeeper residues. J. Mol. Biol. 341(2), 575-588 (2004).
52. Morozova-Roche LA, Zamotin V, Malisauskas M et al. Fibrillation of carrier protein albebetin and its biologically active constructs. Multiple oligomeric intermediates and pathways. Biochemistry 43(30), 9610-9619 (2004).
53. Gosal WS, Morten IJ, Hewitt EW, Smith DA, Thomson NH, Radford SE. Competing pathways determine fibril morphology in the self-assembly of b2-microglobulin into amyloid. J. Mol. Biol. 351(4), 850-864 (2005).
54. Frey HJ, Mattila KM, Korolainen MA, Pirttilä T. Problems associated with biological markers of Alzheimer's disease. Neurochem. Res. 30(12), 1501-1510 (2005). (Pubitemid 41818932)
55. Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9(3), 293-348 (2006).
56. Gustaw-Rothenberg K, Lerner A et al. Biomarkers in Alzheimer's disease: past, present and future. Biomark. Med. 4(1), 15-26 (2010).
57. Korolainen MA, Nyman TA, Aittokallio T, Pirttilä T. An update on clinical proteomics in Alzheimer's research. J. Neurochem. 112(6), 1386-1414 (2010).
58. Tapiola T, Alafuzoff I, Herukka SK et al. Cerebrospinal fluid {b}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66(3), 382-389 (2009).
59. Brunnström H, Rawshani N, Zetterberg H et al. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement. 6(2), 104-109 (2010).
60. Reed TT, Pierce WM, Markesbery WR, Butterfield DA. Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res. 1274, 66-76 (2009).
61. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 184(1-2), 69-91 (2007).
62. Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG. Ab aggregation and possible implications in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 13(3), 412-421 (2009).
63. Alikhani N, Ankarcrona M, Glaser E. Mitochondria and Alzheimer's disease: amyloid-b peptide uptake and degradation by the presequence protease, hPreP. J. Bioenerg. Biomembr. 41(5), 447-451 (2009).
64. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark. Med. 4(1), 27-36 (2010).
65. Doig AJ. Peptide inhibitors of b-amyloid aggregation. Curr. Opin. Drug Discov. Devel. 10(5), 533-539 (2007).
66. Young KJ, Bennett JP. The Mitochondrial Secret(ase) of Alzheimer's Disease. J. Alzheimers Dis. 20(Suppl. 2), 381-400 (2010).
67. Matsunaga Y, Fujii A, Awasthi A, Yokotani J, Takakura T, Yamada T. Eight-residue A-b peptides inhibit the aggregation and enzymatic activity of A-b42. Regul. Pept. 120(1-3), 227-236 (2004).
68. Hirohata M, Ono K, Yamada M. Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. Curr. Pharm. Des. 14(30), 3280-3294 (2008).
69. Polverino de Laureto P, Frare E, Gottardo R, Fontana A. Molten globule of bovine a-lactalbumin at neutral pH induced by heat, trifluoro-ethanol, and oleic acid: a comparative analysis by circular dichroism spectroscopy and limited proteolysis. Proteins 49(3), 385-397 (2002).
70. Svensson M, Mossberg AK, Pettersson J, Linse S, Svanborg C. Lipids as cofactors in protein folding: stereo-specific lipid-protein interactions are required to form HAMLET (human a-lactalbumin made lethal to tumor cells). Protein Sci. 12(12), 2805-2814 (2003).
71. Sinibaldi F, Mei G, Polticelli F, Piro MC, Howes BD, Smulevich G, Santucci R, Ascoli F, Fiorucci L. ATP specifically drives refolding of non-native conformations of cytochrome c. Protein Sci. 14(4), 1049-1058 (2005).
72. Patriarca A, Eliseo T, Sinibaldi F et al. ATP acts as regulatory effector in modulating structural transitions of cytochrome c: implications for apoptotic activity. Biochemistry 48(15), 3279-3287 (2009).
73. Bushnell GW, Louie GV, Brayer GD. High-resolution three-dimensional structure of horse heart cytochrome c. J. Mol. Biol. 214(2), 585-595 (1990).
74. Banci L, Bertini I, Gray HB et al. Solution structure of oxidized horse heart cytochrome c. Biochemistry 36(32), 9867-9877 (1997).
75. Bayir H, Fadeel B, Palladino MJ et al. Apoptotic interactions of cytochrome c: redox flirting with anionic phospholipids within and outside of mitochondria. Biochim. Biophys. Acta 1757(5-6), 648-659 (2006).
76. Berezhna S, Wohlrab H, Champion PM. Resonance Raman investigations of cytochrome c conformational change upon interaction with membranes of intact and Ca2+-exposed mitochondria. Biochemistry 42(20), 6149-6158 (2003).
77. Kagan VE, Borisenko G, Tyurina YY et al. Oxidative lipidomics of apoptosis: redox catalytic interactions of cytochrome c with cardiolipin and phosphatidylserine. Free Radic. Biol. Med. 37(12), 1963-1985 (2004).
78. Sharonov GV, Feofanov AV, Bocharova OV et al. Comparative analysis of proapoptotic activity of cytochrome c mutants in living cells. Apoptosis 10(4), 797-808 (2005).
79. Lewis RN, McElhaney RN. The physicochemical properties of cardiolipin bilayers and cardiolipin-containing lipid membranes. Biochim. Biophys. Acta 1788(10), 2069-2079 (2009).
80. Kagan VE, Bayir HA, Belikova NA et al. Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic. Biol. Med. 46(11), 1439-1453 (2009).
81. Caroppi P, Sinibaldi F, Fiorucci L, Santucci R. Apoptosis and human diseases: mitochondrion damage and lethal role of released cytochrome c as proapoptotic protein. Curr. Med. Chem. 16(31), 4058-4065 (2009).
82. Sinibaldi F, Fiorucci L, Patriarca A et al. Insights into cytochrome c-cardiolipin interaction. Role played by ionic strength. Biochemistry 47(26), 6928-6935 (2008).
83. Rytömaa M, Kinnunen PKJ. Reversibility of the binding of cytochrome c to liposomes. Implications for lipid-protein interactions. J. Biol. Chem. 270 (7), 3197-3202 (1995).
84. Kalanxhi E, Wallace CJA. Cytochrome c impaled: investigation of the extended lipid anchorage of a soluble protein to mitochondrial membrane models. Biochem. J. 407(2), 179-187 (2007).
85. Sinibaldi F, Howes BD, Piro MC et al. Extended cardiolipin anchorage to cytochrome c: a model for protein-mitochondrial membrane binding. J. Biol. Inorg. Chem. 15(5), 689-700 (2010).
86. Schug ZT, Gottlieb E. Cardiolipin acts as a mitochondrial signaling platform to launch apoptosis. Biochim. Biophys. Acta 1788(10), 2022-2031 (2009).
87. Hoye AT, Davoren JE, Wipf, Fink MP, Kagan VE. Targeting mitochondria. Acc. Chem. Res. 41(1), 87-97 (2008).
88. Kagan VE, Tyurin VA, Jiang J et al. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat. Chem. Biol. 1(4), 223-232 (2005).
89. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9(1), 47-59 (2008).
90. Brown GC, Borutaite V. Regulation of apoptosis by the redox state of cytochrome c. Biochim Biophys Acta 1777 (7-8), 877-881 (2008).
91. Vaughn AE, Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat. Cell. Biol. 10(12), 1477-1483 (2008).
92. Martin HL, Teismann P. Glutathione-a review on its role and significance in Parkinson's disease. FASEB J. 23(10), 3263-3272 (2009).
93. Fatokun AA, Stone TW, Smith RA. Oxidative stress in neurodegeneration and available means of protection. Front. Biosci. 13, 3288-3311 (2008).
94. Borutaite V. Mitochondria as decision-makers in cell death. Environ. Mol. Mutagen. 51(5), 406-416 (2010).
95. Bayir H, Kapralov AA, Jiang J et al. Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome c: protection against apoptosis versus delayed oxidative stress in Parkinson disease. J. Biol. Chem. 284, 15951-15969 (2009).
96. Gao HM, Kotzbauer PT, Uryu K et al. Neuroinflammation and oxidation/ nitration of a-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 23 7687-7698 (2008).
97. Cherra SJ 3rd, Dagda RK, Chu CT. Review: autophagy and neurodegeneration: survival at a cost? Neuropathol. Appl. Neurobiol. 36, 125-132 (2010).
98. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav. Brain Res. 196(2), 168-179 (2009).
99. Schulenborg T, Schmidt O, van Hall A, Meyer HE, Hamacher M, Marcus K. Proteomics in neurodegeneration-disease driven approaches. J. Neural Transm. 113(8), 1055-1073 (2006).
100. Everse J, Coates PW. Neurodegeneration and peroxidases. Neurobiol. Aging 30, 1011-1025 (2009).
101. Garcia-Martinez EM, Sanz-Blasco S, Karachitos A et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem. Pharmacol. 79(2), 239-250 (2010).
102. Kagan VE, Wipf P, Stoyanovsky D et al. Mitochondrial targeting of electron scavenging antioxidants: regulation of selective oxidation vs random chain reactions. Adv. Drug Deliv. Rev. 61, 1375-1385 (2009).